Cogent Biosciences (COGT) Q3 2026 earnings summary

Executive summary

• Three bezuclastinib NDAs are under FDA review: PDUFA dates are Nov. 30, 2026 for GIST, Dec. 30, 2026 for NonAdvSM and June 29, 2027 for AdvSM.

• Positive Phase 3 PEAK results in second-line GIST and positive SUMMIT and APEX results underpin a planned U.S. launch in H2 2026, pending approval; the commercial team is in place.

• No product sales revenue to date; 9M net loss was $305.2M, and cash, cash equivalents and marketable securities totaled $791.1M at Sept. 30, 2026.

Financial highlights

• Q3 2026 operating expenses were $117.2M vs. $83.4M YoY; operating loss was $117.2M vs. $83.4M and net loss was $111.4M vs. $80.9M.

• Q3 R&D was $75.1M vs. $69.0M YoY; G&A was $42.1M vs. $14.4M, reflecting clinical, regulatory, pre-launch and commercial-readiness spending.

• 9M 2026 operating expenses were $323.4M vs. $233.9M; net loss was $305.2M vs. $226.4M, and common-stock loss per share was $1.65 vs. $1.55.

• Q3 interest income rose to $7.1M from $3.9M YoY; 9M interest income was $22.1M vs. $9.2M.

Outlook and guidance

• Cash, cash equivalents and marketable securities are expected to fund operating expenses and capital spending into late 2028, beyond all three pending bezuclastinib PDUFA dates; estimates rely on assumptions that may prove incorrect.

• U.S. commercial launch of bezuclastinib is targeted for H2 2026, subject to regulatory approval; expenses are expected to rise with launch preparation and pipeline development.

• IND applications for CGT1815, a pan-KRAS (ON) inhibitor, and CGT1145, a JAK2 V617F inhibitor, are planned for Q4 2026; CGT4255 dose escalation is to be completed.